On Thursday, Evolus got a positive adjustment to its Relative Strength (RS) Rating, from 76 to 81.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History reveals that the best stocks typically have an RS Rating north of 80 as they begin their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Evolus is trying to complete a with a 17.12 entry. See if the stock can break out in heavy trading.
Evolus reported 0% EPS growth in the latest quarterly report, while sales growth came in at 29%.
The company earns the No. 17 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR, Phibro Animal Health and Protagonist Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
